There are no associated toxicities with almotriptan due to the limited data, although studies demonstrate increased preterm birth rates in pregnant women that received triptans for migraine relief.

An analysis of several case reports of patients undergoing dual triptan-SSRI/SNRI, e.g., fluoxetine and venlafaxine, therapy or triptan monotherapy, suggested addingÂ triptans to SSRI/SNRI therapy does not necessarily increase patients' risk of developing serotonin syndrome. However, providers should remain cautious and vigilant of the symptoms.